Skip to content Skip to footer
Subscribe Now
NEWS

Italfarmaco Collaborates with VeriSIM Life to Develop Novel HDAC-Targeting Therapeutics

Shots: Italfarmaco & VeriSIM Life have entered into a strategic collaboration to discover & develop novel histone deacetylase (HDAC)-targeted therapeutic assets for neuromuscular, fibrotic, & rare diseases As per the deal, VeriSIM Life will receive technology service fees, development, regulatory, & commercial milestone payments, and royalties on future commercial products, with the total potential value…
11 hours ago

Read more

NEWS

Novartis Reports del-desiran P-III HARBOR Study Data in Myotonic Dystrophy Type 1

Shots: Novartis announced that the P-III HARBOR study of delpacibart etedesiran (del-desiran) in people with myotonic dystrophy type 1 (DM1) did not meet its 1EP of video hand opening time (vHOT) Del-desiran showed evidence of clinical activity in 2EPs and exploratory analyses, while safety findings were generally consistent with previously reported data; Novartis is evaluating…
September 8, 2026

Read more

VIEWPOINTS_Kathleen Somera-Molina_2023
VIEWPOINTS

Kathleen Somera-Molina, Head of SMA Global Medical Affairs at Biogen Shares Insights on New SPINRAZA (nusinersen) Long-Term Data in SMA

Shots: Kathleen spoke about new long-term SPINRAZA (nusinersen) data presented at the 3rd International Scientific Congress She then explained the new findings from individuals with infantile-onset SMA who were treated with SPINRAZA in the pivotal ENDEAR study followed by the long-term extension SHINE study for up to 7 years The interview also discusses Biogen’s advances…
August 7, 2023

Read more

VIEWPOINTS_Kathleen Somera-Molina1_2023
VIEWPOINTS

Kathleen Somera-Molina, Head of SMA Global Medical Affairs at Biogen Shares Insights on New Data Published about SPINRAZA

Shots: Kathleen spoke about the results of a new study published in Advances in Therapy evaluating real-world adherence to SPINRAZA (nusinersen) with its unique dosing schedule among people with spinal muscular atrophy (SMA) She also talked about the overall adherence rates to nusinersen. She highlighted that adherence was higher during the maintenance phase than the loading phase…
July 24, 2023

Read more